News >

Frontline Lenalidomide/R-CHOP Combo Misses Primary Endpoint in DLBCL

Gina Columbus @ginacolumbusonc
Published: Friday, Apr 26, 2019

blood cells The combination of lenalidomide (Revlimid) with rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; R2-CHOP) did not improve progression-free survival (PFS) compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell (ABC)-type diffuse large B-cell lymphoma (DLBCL), missing the primary endpoint of the phase III ROBUST trial.1



  1. Celgene Reports First Quarter 2019 Operating and Financial Results. Celgene. Published April 25, 2019. Accessed April 25, 2019.
  2. Nowakowski GS, Chiappella A, Witzig TE, et al. Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST). J Clin Oncol. 2018;36 (suppl 15; abstr 7548). doi: 10.1200/JCO.2018.36.15_suppl.7548.
  3. Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33(3):251-257. doi: 10.1200/JCO.2014.55.5714.
  4. Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15(7):730-737. doi: 10.1016/S1470-2045(14)70191-3.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication